Data Exclusivity
A regulatory protection period during which generic or biosimilar applicants cannot rely on the originator's clinical data to support their own approval application. In the US, new chemical entities receive 5 years of data exclusivity. This is separate from and may run concurrently with patent protection.
Technical Context
US data exclusivity: 5 years for new chemical entities (NCEs), 3 years for new clinical studies supporting a new indication/formulation of an already-approved drug, and 12 years for biologics (under BPCIA). During the exclusivity period, the FDA will not accept or approve applications that reference the originator's data. Data exclusivity is independent of patents — it provides a guaranteed protection period even if patents are challenged or invalidated. EU data exclusivity: 8 years of data protection (no generic/biosimilar application can be submitted), followed by 2 years of market protection (application can be submitted but product cannot be marketed), plus potential 1-year extension for a new indication with significant clinical benefit (8+2+1 formula). Data exclusivity is particularly important for peptide drugs because some peptide sequences may not be patentable (natural sequences cannot be patented).